Multi-analyte ADC PK/PD and exposure-driven dose selection — therapeutic window and OBD from conjugate efficacy vs. free-payload toxicity, the toxicology paradigm (not MABEL).
adcdarpkpdimmuno-oncologypkpd-modellingantibody-drug-conjugatesdose-selectionmulti-analytetherapeutic-index
-
Updated
Jul 2, 2026 - Python